

LEGISLATIVE BUDGET BOARD

Austin, Texas

FISCAL NOTE, 78TH LEGISLATIVE REGULAR SESSION

April 29, 2003

TO: Honorable Jaime Capelo, Chair, House Committee on Public Health

FROM: John Keel, Director, Legislative Budget Board

IN RE: HB2046 by Deshotel (Relating to a prescription drug cost control education program and disclosure of certain expenditures by prescription drug manufacturers.), **As Introduced**

No significant fiscal implication to the State is anticipated.

The bill would require pharmaceutical manufacturing companies that do business in the state to submit an annual report to the Texas Department of Health (TDH) and the Texas State Board of Pharmacy (TSBP). The bill would require the annual report to disclose the value, nature, and purpose of any gift, fee, payment, subsidy, or other economic benefit received by certain health care providers in connection with promotional or marketing activities of the company. TSBP would be required to develop the form for the report. TDH would be required to develop strategies to educate providers about the cost-effective use of prescription drugs.

The bill would be effective on September 1, 2003.

It is assumed that the provisions of the bill could be implemented using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 302 Office of the Attorney General, 501 Department of Health, 515 Board of Pharmacy

LBB Staff: JK, EB, KF, AJ, TG